July 3 (Reuters) - Antibe Therapeutics Inc ATE.V :
* ANTIBE THERAPEUTICS RELEASES SECONDARY ENDPOINT DATA FROM RECENT PHASE 2B GASTROINTESTINAL SAFETY STUDY FOR LEAD DRUG, ATB-346
* ANTIBE THERAPEUTICS INC - SECONDARY GI SAFETY ENDPOINT DATA FOR ATB-346 ARE CONSISTENT WITH PRIMARY ENDPOINT DATA